Literature DB >> 24198407

A targeted mutation within the feline leukemia virus (FeLV) envelope protein immunosuppressive domain to improve a canarypox virus-vectored FeLV vaccine.

Géraldine Schlecht-Louf1, Marianne Mangeney, Hanane El-Garch, Valérie Lacombe, Hervé Poulet, Thierry Heidmann.   

Abstract

We previously delineated a highly conserved immunosuppressive (IS) domain within murine and primate retroviral envelope proteins that is critical for virus propagation in vivo. The envelope-mediated immunosuppression was assessed by the ability of the proteins, when expressed by allogeneic tumor cells normally rejected by engrafted mice, to allow these cells to escape, at least transiently, immune rejection. Using this approach, we identified key residues whose mutation (i) specifically abolishes immunosuppressive activity without affecting the "mechanical" function of the envelope protein and (ii) significantly enhances humoral and cellular immune responses elicited against the virus. The objective of this work was to study the immunosuppressive activity of the envelope protein (p15E) of feline leukemia virus (FeLV) and evaluate the effect of its abolition on the efficacy of a vaccine against FeLV. Here we demonstrate that the FeLV envelope protein is immunosuppressive in vivo and that this immunosuppressive activity can be "switched off" by targeted mutation of a specific amino acid. As a result of the introduction of the mutated envelope sequence into a previously well characterized canarypox virus-vectored vaccine (ALVAC-FeLV), the frequency of vaccine-induced FeLV-specific gamma interferon (IFN-γ)-producing cells was increased, whereas conversely, the frequency of vaccine-induced FeLV-specific interleukin-10 (IL-10)-producing cells was reduced. This shift in the IFN-γ/IL-10 response was associated with a higher efficacy of ALVAC-FeLV against FeLV infection. This study demonstrates that FeLV p15E is immunosuppressive in vivo, that the immunosuppressive domain of p15E can modulate the FeLV-specific immune response, and that the efficacy of FeLV vaccines can be enhanced by inhibiting the immunosuppressive activity of the IS domain through an appropriate mutation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24198407      PMCID: PMC3911645          DOI: 10.1128/JVI.02234-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Vaccination against the feline leukaemia virus: outcome and response categories and long-term follow-up.

Authors:  Regina Hofmann-Lehmann; Valentino Cattori; Ravi Tandon; Felicitas S Boretti; Marina L Meli; Barbara Riond; Andrea C Pepin; Barbara Willi; Pete Ossent; Hans Lutz
Journal:  Vaccine       Date:  2006-12-28       Impact factor: 3.641

Review 2.  Common threads in persistent viral infections.

Authors:  Melissa Kane; Tatyana Golovkina
Journal:  J Virol       Date:  2009-12-02       Impact factor: 5.103

3.  Retroviral infection in vivo requires an immune escape virulence factor encrypted in the envelope protein of oncoretroviruses.

Authors:  Géraldine Schlecht-Louf; Martial Renard; Marianne Mangeney; Claire Letzelter; Aurélien Richaud; Bertrand Ducos; Isabelle Bouallaga; Thierry Heidmann
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-08       Impact factor: 11.205

4.  Feline leukemia virus immunity induced by whole inactivated virus vaccination.

Authors:  Andrea N Torres; Kevin P O'Halloran; Laurie J Larson; Ronald D Schultz; Edward A Hoover
Journal:  Vet Immunol Immunopathol       Date:  2009-10-31       Impact factor: 2.046

5.  Placental syncytins: Genetic disjunction between the fusogenic and immunosuppressive activity of retroviral envelope proteins.

Authors:  Marianne Mangeney; Martial Renard; Géraldine Schlecht-Louf; Isabelle Bouallaga; Odile Heidmann; Claire Letzelter; Aurélien Richaud; Bertrand Ducos; Thierry Heidmann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-12       Impact factor: 11.205

6.  Epizootiology and management of feline leukemia virus in the Florida puma.

Authors:  Mark W Cunningham; Meredith A Brown; David B Shindle; Scott P Terrell; Kathleen A Hayes; Bambi C Ferree; R T McBride; Emmett L Blankenship; Deborah Jansen; Scott B Citino; Melody E Roelke; Richard A Kiltie; Jennifer L Troyer; Stephen J O'Brien
Journal:  J Wildl Dis       Date:  2008-07       Impact factor: 1.535

Review 7.  Strategies for use of IL-10 or its antagonists in human disease.

Authors:  Anne O'Garra; Franck J Barrat; Antonio G Castro; Alain Vicari; Catherine Hawrylowicz
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

8.  Exposure of cats to low doses of FeLV: seroconversion as the sole parameter of infection.

Authors:  Andrea Major; Valentino Cattori; Eva Boenzli; Barbara Riond; Peter Ossent; Marina Luisa Meli; Regina Hofmann-Lehmann; Hans Lutz
Journal:  Vet Res       Date:  2009-10-28       Impact factor: 3.683

Review 9.  Feline leukemia virus infection: a threat for the survival of the critically endangered Iberian lynx (Lynx pardinus).

Authors:  Marina L Meli; Valentino Cattori; Fernando Martínez; Guillermo López; Astrid Vargas; Francisco Palomares; José V López-Bao; Regina Hofmann-Lehmann; Hans Lutz
Journal:  Vet Immunol Immunopathol       Date:  2009-10-14       Impact factor: 2.046

10.  Gene profiling analysis of ALVAC infected human monocyte derived dendritic cells.

Authors:  Anke Harenberg; Florine Guillaume; Elizabeth J Ryan; Nicolas Burdin; Franca Spada
Journal:  Vaccine       Date:  2008-08-06       Impact factor: 3.641

View more
  12 in total

1.  Immunosuppression in a Comparative Study of Feline Leukemia Virus Vaccines.

Authors:  Hervé Poulet; Jean-Christophe Thibault; Alonso Masias
Journal:  Clin Vaccine Immunol       Date:  2015-12

2.  Reply to "Immunosuppression in a Comparative Study of Feline Leukemia Virus Vaccines".

Authors:  M Patel; K Carritt; J Lane; H Jayappa; M Stahl; M Bourgeois
Journal:  Clin Vaccine Immunol       Date:  2015-12

Review 3.  Implication of human endogenous retrovirus envelope proteins in placental functions.

Authors:  Adjimon Gatien Lokossou; Caroline Toudic; Benoit Barbeau
Journal:  Viruses       Date:  2014-11-24       Impact factor: 5.048

4.  Establishment of a yeast-based VLP platform for antigen presentation.

Authors:  David Wetzel; Theresa Rolf; Manfred Suckow; Andreas Kranz; Andreas Barbian; Jo-Anne Chan; Joachim Leitsch; Michael Weniger; Volker Jenzelewski; Betty Kouskousis; Catherine Palmer; James G Beeson; Gerhard Schembecker; Juliane Merz; Michael Piontek
Journal:  Microb Cell Fact       Date:  2018-02-05       Impact factor: 5.328

5.  Antigenicity of peptides comprising the immunosuppressive domain of the retroviral envelope glycoprotein.

Authors:  Bryony Jenkins; Urszula Eksmond; George Young; George Kassiotis
Journal:  Wellcome Open Res       Date:  2016-12-06

6.  A human endogenous retrovirus-derived gene that can contribute to oncogenesis by activating the ERK pathway and inducing migration and invasion.

Authors:  Cécile Lemaître; Jhen Tsang; Caroline Bireau; Thierry Heidmann; Marie Dewannieux
Journal:  PLoS Pathog       Date:  2017-06-26       Impact factor: 6.823

7.  Infection with koala retrovirus subgroup B (KoRV-B), but not KoRV-A, is associated with chlamydial disease in free-ranging koalas (Phascolarctos cinereus).

Authors:  Courtney A Waugh; Jonathan Hanger; Joanne Loader; Andrew King; Matthew Hobbs; Rebecca Johnson; Peter Timms
Journal:  Sci Rep       Date:  2017-03-09       Impact factor: 4.379

8.  Interference of retroviral envelope with vaccine-induced CD8+ T cell responses is relieved by co-administration of cytokine-encoding vectors.

Authors:  Nadine Bongard; Dennis Lapuente; Sonja Windmann; Ulf Dittmer; Matthias Tenbusch; Wibke Bayer
Journal:  Retrovirology       Date:  2017-04-27       Impact factor: 4.602

9.  Protection from Hendra virus infection with Canarypox recombinant vaccine.

Authors:  Vanessa Guillaume-Vasselin; Laurent Lemaitre; Kévin P Dhondt; Laurence Tedeschi; Amelie Poulard; Catherine Charreyre; Branka Horvat
Journal:  NPJ Vaccines       Date:  2016-07-28       Impact factor: 7.344

Review 10.  Tracking the Continuous Evolutionary Processes of an Endogenous Retrovirus of the Domestic Cat: ERV-DC.

Authors:  Junna Kawasaki; Kazuo Nishigaki
Journal:  Viruses       Date:  2018-04-06       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.